{"id":"W2922280445","doi":"10.1002/art.40866","title":"A Fifty‐Two–Week, Randomized, Placebo‐Controlled Trial of Certolizumab Pegol in Nonradiographic Axial Spondyloarthritis","year":2019,"lang":"en","type":"article","venue":"Arthritis & Rheumatology","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":101,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto; University Health Network; University of Alberta","funders":"UCB Pharma; Pfizer; Eli Lilly and Company; Amgen","keywords":"Certolizumab pegol; Medicine; Placebo; Clinical endpoint; Internal medicine; Ankylosing spondylitis; Randomized controlled trial; Axial spondyloarthritis; Surgery; Physical therapy; Disease; Sacroiliitis; Adalimumab; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001486297,0.001388788,0.002987589,0.0004969541,0.0006331179,0.0008153337,0.0008492011,0.00183481,0.006174923],"category_scores_gemma":[0.0019083,0.0008357689,0.001104241,0.0003815401,0.00133781,0.0008846459,0.0004440638,0.002201457,0.001090283],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005170704,"about_ca_system_score_gemma":0.001194674,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007730272,"about_ca_topic_score_gemma":0.001634988,"domain_scores_codex":[0.9992855,0.0003495076,0.00006290345,0.000134564,0.0000569683,0.0001106148],"domain_scores_gemma":[0.9990321,0.0002966836,0.0001989859,0.00008218769,0.00006101674,0.0003290133],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9820613,0.005882589,0.0004262219,0.0004272909,0.0003407984,0.0000301504,0.00004375661,0.0001532394,0.002753196,0.00004649531,0.0003076371,0.007527416],"study_design_scores_gemma":[0.9738942,0.0245351,0.0009792978,0.00001182766,0.0001081512,0.00001001875,0.000008489996,0.0001290887,0.0001456095,0.00002695322,0.0001461561,0.000004983886],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.990457,0.002179017,0.0005212242,0.000397654,0.0004435485,0.004041867,0.0005739662,0.0001246082,0.001261027],"genre_scores_gemma":[0.9870759,0.001604177,0.001317749,0.000855267,0.0003671452,0.00574407,0.0006533066,0.00001629387,0.002366127],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006174923,"threshold_uncertainty_score":0.02065718,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.007715533130576363,"score_gpt":0.2472922794934098,"score_spread":0.2395767463628334,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}